Francesco Cortiula
@FCortiula
Followers
356
Following
676
Media
3
Statuses
296
Medical Oncologist- #lungcancer #thoracic #oncology #protontherapy @UdineUniversityHospital PhD candidate @MaastrichtU @MaastrichtUMC @MAASTRO
Udine, Italy
Joined March 2020
Can we de-escalate ICIs in NSCLC?💡.Are we ready to reduce financial and patients' tox?🔎. Honoured to work on this topic with terrific colleagues.@HendriksLizza @JordiRemon @JessicaMenis @g_mountzios @BenjaminBesseMD @MarianaBrandao0 @NReguart @MartinaBortolot.
De-Escalation Strategies With ICIs in NSCLC: Do We Already Have Enough Evidence? @JCO_ASCO . Pleased to contribute to this great review led by @JordiRemon @GustaveRoussy @OncoAlert @g_mountzios @HendriksLizza @FCortiula @JessicaMenis @MarianaBrandao0 #LCSM
0
5
13
RT @StephenVLiu: Press release updates data for NVL-520, zidesamtinib, in #ROS1 NSCLC. In 117 pts who had prior TKI (half had 2+ TKIs), RR….
0
17
0
RT @myESMO: 📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents n….
0
15
0
RT @myESMO: 📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options appr….
0
17
0
RT @DrJNaidoo: #ASCO25 Developmental Therapeutics CSS🔥. Ph III DELLI trial: ultra-low dose nivo in 2L all solid tumors v chemo @VanitaNoron….
0
5
0
RT @DoctorJSpicer: Why is CM816 so important? After @FordePatrick beautiful presentation of these revolutionary data, let’s dig into why th….
0
33
0
RT @StephenVLiu: #ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs….
0
39
0
RT @tnewsomdavis: IMforte: lurbinectedin + atezo maintenance ES-SCLC. ✅ ⬆️ mPFS 5.4 v 2.1m, HR 0.54.✅ ⬆️ mOS 13.2 v 10.6m, HR 0.73.✅ ⬆️ ORR….
0
15
0
RT @FordePatrick: Remarkable results in pretreated EGFR mutant lung cancer! In global trial, stellar benefit in progression-free survival f….
0
6
0
RT @DrJNaidoo: Fascinating paper @NatureCancer on mechanisms of resistance to TIL in NSCLC:. - serial multiomic analysis, 16pt TIL trial .-….
0
22
0
RT @ADesaiMD: In @JTOonline #BRAF-mutated #NSCLC: 📊 1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows:….
0
12
0
Congrats to all the authors for this great collaborative effort🏆. ICI retreatment after durvalumab for relapsed stage III NSCLC should be offered to selected patients💥📢. These results also confirm our previous findings🎯.@HendriksLizza.@AndrearicFili.
Real world outcomes in pts with relapse after durvalumab consolidation post CRT for stage III NSCLC @LungCaJournal. With chemo-immunotherapy, PFS 12m; with platinum-based chemo alone, PFS 4.1m; non-platinum based chemo PFS 2.7m; targeted therapy PFS 6m.
0
3
9
RT @JordiRemon: Personalised approach at osimertinib PD with savolitinib and osimertinib in MET deregulated EGFRm NSCLC looks promising. Is….
0
35
0
RT @JordiRemon: We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Da….
0
33
0
RT @HHorinouchi: 🔥European Journal of Cancer🆙.✅Efficacy of Immunotherapy retreatment vs Chemo in Unresectable NSCLC with Progression Post C….
0
10
0
RT @AndrearicFili: Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post….
0
9
0
RT @myESMO: 📣 Just updated: ESMO Non-oncogene-addicted mNSCLC Living Guideline v1.2.👉Find new recommendations with links to ESMO-MCBS score….
0
11
0
RT @JordiRemon: IO has changed ttx and outcome in adv 🫁.It’s time that Academic trials (PULSE @BenjaminBesseMD )and international grants te….
0
24
0
The landscape in mNSCLC Is constantly evolving🧑⚕️.Thanks @myESMO for this great tool💥.
📣 Just updated: ESMO Oncogene-addicted mNSCLC Living Guideline v1.2. 🧬 Find new recommendations with links to ESMO-MCBS scores, easily accessible from desktop and mobile devices. #ESMOGuidelines. 🔗
0
1
7